Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 5

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 5
---
, reduce or terminate the development of our Alpha DaRT technology or
plans for commercialization.

We believe that our existing
cash and cash equivalents will enable us to fund its operating expenses and capital expenditure requirements into 2026. Our estimates
may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances,
some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may
need to seek additional funds sooner than planned.

Our limited operating history may make it
difficult for you to evaluate the success of our business to date and to assess our future viability.

We are a clinical-stage, medical
device, oncology therapeutics company with a limited operating history. We commenced operations in 2016, and our operations to date have
been limited to organizing and staffing our company, business planning, raising capital, conducting research activities, filing patent
applications, developing our Alpha DaRT technology, identifying target indications, initiating and conducting our clinical trials, undertaking
preclinical studies and establishing manufacturing infrastructure and capacity to produce our Alpha DaRT technology. We have not yet demonstrated
our ability to successfully complete a pivotal trial in the United States, obtain marketing authorizations (other than in Israel) or similar
authorizations or certifications in other foreign jurisdictions, manufacture a commercial-scale product or arrange for a third party to
do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently,
any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.

In addition, as a pre-revenue
business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need
to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities.
We may not be successful in such a transition.

We may be exposed to financial risk related
to the fluctuation of foreign exchange rates and the degrees of volatility of those rates.

We may be adversely affected
by foreign currency fluctuations. Our reporting currency and the functional currency of our operating companies is the US Dollar. To date,
we have been primarily funded through issuances of equity that have been denominated in U. S. Dollar. However, a meaningful portion of
our expenditures are paid in New Israeli Shekel, particularly with respect to our employees, and we are therefore subject